

1 **Accessory Genomes Drive Independent Spread of Carbapenem-Resistant**

2 ***Klebsiella pneumoniae* Clonal Groups 258 and 307**

3 William C Shropshire^{1,2}, An Q Dinh², Michelle Earley³, Lauren Komarow³, Diana Panesso^{2,4,5},
4 Kirsten Rydell^{1,2}, Sara I Gómez-Villegas², Hongyu Miao⁶, Carol Hill⁷, Liang Chen⁸, Robin
5 Patel⁹, Bettina C Fries^{10,11}, Lilian Abbo¹², Eric Cober¹³, Sara Revolinski¹⁴, Courtney L
6 Luterbach¹⁵, Henry Chambers¹⁶, Vance G Fowler¹⁷, Robert A Bonomo^{2,18,19}, Samuel A
7 Shelburne^{2,20,21}, Barry N Kreiswirth⁸, David van Duin¹⁵, Blake M Hanson^{1,2*}, Cesar A
8 Arias^{1,2,4,5*}

9 ¹Center for Infectious Diseases, School of Public Health, University of Texas Health Science
10 Center, Houston, Texas, 77030 USA

11 ²Center for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases,
12 University of Texas Health Science Center at Houston McGovern Medical School, Houston,
13 Texas, 77030 USA

14 ³The Biostatistics Center, The George Washington University, Rockville, MD, USA

15 ⁴Department of Microbiology and Molecular Genetics, University of Texas McGovern Medical
16 School at Houston, Houston, Texas, 77030 USA

17 ⁵Molecular Genetics and Antimicrobial Resistance Unit-International Center for Microbial
18 Genomics, Universidad El Bosque, Bogotá, Colombia

19 ⁶Department of Biostatistics and Data Science, School of Public Health, University of Texas
20 Health Science Center, Houston, Texas, 77030 USA

21 ⁷Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

- 22 ⁸Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA
- 23 ⁹Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and
24 Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
- 25 ¹⁰Department of Medicine, Infectious Disease Division, Stony Brook University, Stony Brook,
26 NY, USA
- 27 ¹¹Veteran's Administration Medical Center, Northport, New York, USA
- 28 ¹²Division of Infectious Diseases, Department of Medicine, University of Miami Miller School
29 of Medicine and Jackson Health System, Miami, FL, USA
- 30 ¹³Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH, USA
- 31 ¹⁴School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI, USA
- 32 ¹⁵Division of Infectious Diseases, University of North Carolina at Chapel Hill, Raleigh, NC ,
33 USA
- 34 ¹⁶Department of Medicine, University of California San Francisco, San Francisco, USA
- 35 ¹⁷Division of Infectious Diseases, Duke University, Durham, NC, USA
- 36 ¹⁸Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and
37 Proteomics and Bioinformatics, Case Western Reserve University School of Medicine,
38 Cleveland, OH, USA
- 39 ¹⁹CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology, Cleveland,
40 OH, USA
- 41 ²⁰Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center,
42 Houston, Texas, USA
- 43 ²¹Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center,
44 Houston, Texas, USA

45 *Address correspondence to Cesar A. Arias, MD, PhD, 6431 Fannin St., MSB 1.150, (713) 500-
46 6738, cesar.arias@uth.tmc.edu, and Blake Hanson, PhD, 1200 Pressler St., E739, Houston, TX
47 77030 (713) 500-9357, blake.hanson@uth.tmc.edu.

48 **Abstract**

49 **Background:**

50 Carbapenem-resistant *Klebsiella pneumoniae* (CRKp) are urgent public health threats.
51 Worldwide dissemination of CRKp has been largely attributed to the clonal group (CG) 258.
52 However, recent evidence indicates the global emergence of a CRKp CG307 lineage. Houston,
53 Texas is the first large city in the US with co-circulation of both CRKp CG307 and CG258. We
54 sought to characterize the genomic and clinical factors contributing to the parallel endemic
55 spread of CG258 and CG307.

56 **Methods:**

57 CRKp isolates were collected as part of the prospective, Consortium on Resistance Against
58 Carbapenems in *Klebsiella* and other *Enterobacteriales* 2 (CRACKLE-2) study. Hybrid short-
59 read and long-read genome assemblies were generated from 119 CRKp isolates (95 originated
60 from Houston hospitals). A comprehensive characterization of phylogenies, gene transfer, and
61 plasmid content with pan-genome analysis were performed on all CRKp isolates. Plasmid mating
62 experiments were performed with CG307 and CG258 isolates of interest. An inverse-probability
63 weighted Desirability of Ordinal Outcome Ranking (DOOR) analysis was conducted to
64 determine if patients infected/colonized with CG307 had differences in overall clinical outcomes
65 from patients infected/colonized with CG258.

66 **Results:**

67 Dissection of the accessory genomes suggested independent evolution and limited horizontal
68 gene transfer between CG307 and CG258 lineages. CG307 contained a diverse repertoire of
69 mobile genetic elements harboring carbapenemases, which were shared with other non-CG258
70 *K. pneumoniae* isolates. Three unique clades of Houston CG307 isolates contained a diverse
71 repertoire of mobile genetic elements harboring carbapenemases and clustered distinctly from
72 other global CG307 isolates. CG307 were often isolated from the urine of hospitalized patients,
73 likely serving as important reservoirs for genes encoding carbapenemases and extended-
74 spectrum beta-lactamases. The DOOR probability estimate (64%; 95% CI: 48, 79) of our
75 Houston-based cohort suggested that there was a general trend for patients infected/colonized
76 with CG307 to have more favorable outcomes than patients infected/colonized with CG258.

77 **Conclusions:**

78 Our findings suggest parallel co-circulation of high-risk lineages with potentially divergent
79 evolution. CG307 is widely circulating CRKp clone in the Houston region with the potential to
80 transfer major resistance determinants to other non-CG258 CRKp lineages. Our findings provide
81 major insights into the mechanism of epidemic spread of CRKp.

82 **Keywords:**

83 Carbapenem-resistant *Klebsiella pneumoniae*, mobile genetic elements, genomic surveillance,
84 divergent evolution

85 **Background**

86 Carbapenem-resistant *Klebsiella pneumoniae* (CRKp) cause significant worldwide morbidity and
87 mortality and are of paramount concern in nosocomial settings (1). Since the identification of *K.*
88 *pneumoniae* isolates harboring the carbapenem-hydrolyzing enzyme *K. pneumoniae*
89 carbapenemase (KPC) in 1996, global dissemination of CRKp has occurred (2). CRKp now
90 make up the majority of carbapenem-resistant *Enterobacteriales* (CRE) infections in the United
91 States (3, 4). Infections caused by CRKp are difficult to treat since these isolates often harbor
92 resistance to multiple antibiotics, limiting therapeutic options (5).

93 Global dissemination of CRKp has been largely attributed to the clonal expansion of a genetic
94 lineage of *K. pneumoniae* designated clonal group 258 (CG258), first identified in the United
95 States in 2008 (6-8). Spread of CG258 has been associated with carriage of genes encoding the
96 KPC enzyme (6, 9) on F-type pKpQIL plasmids (10). More recently, another CRKp genetic
97 lineage, designated CG307, has emerged and appears to be spreading in countries such as Italy,
98 Pakistan, Colombia, and the United States (11-13). Isolates in the *K. pneumoniae* CG307 lineage
99 carry distinct genomic features that may confer virulence and colonization advantages, such as F-
100 type plasmid-borne glycogen synthesis gene clusters and urea transport systems (12). These
101 potential virulence determinants are present in conjunction with established pathogenic factors,
102 such as the *mrk* gene cluster (encoding a type 3 pili), and extracellular polysaccharides (capsule
103 and lipopolysaccharides) found across all MDR *K. pneumoniae* lineages (14). Carriage of *bla*_{KPC}
104 on pKpQIL and N-type plasmids in CG307 isolates has been documented (12); however, not at
105 the same prevalence as CG258. There is a strong association of the CG307 lineage with the
106 carriage of *bla*_{CTX-M-15}, a gene encoding an extended-spectrum β -lactamase (ESBL) (11). Of

107 interest, a molecular dating analysis estimated that CG307 arose in 1994 (11) near the estimated
108 year of emergence of CG258 (6), suggesting that these two high-risk genetic lineages have
109 evolved in parallel.

110 A recent large US cohort study of patients infected or colonized with CRE (Consortium on
111 Resistance Against Carbapenems in *Klebsiella* and other *Enterobacterales* 2 – CRACKLE-2
112 study) identified *K. pneumoniae* CG307 as the second most common lineage of CRKp after
113 CG258 (7% vs 64% out of 593 isolates, respectively) (3). Of note, in that study, the majority
114 (72%) of the CG307 *K. pneumoniae* isolates were found in the Houston, TX metropolitan region.
115 This observation is in agreement with previous reports describing the molecular epidemiology of
116 multidrug-resistant *K. pneumoniae* in a hospital network in Houston, TX (15). Furthermore, the
117 CRACKLE-2 results suggested that Houston had become the first large city in the United States
118 with high endemicity of CRKp where *K. pneumoniae* CG307 and CG258 appear to be co-
119 circulating and undergoing parallel expansion. It is unclear how these respective lineages were
120 introduced in the same geographical region, share antimicrobial resistance and virulence
121 determinants, and to what extent these clonal groups impact clinical outcomes.

122 To dissect factors that drove the parallel co-circulation of CG307 and CG258, as well as the high
123 endemicity of CRKp in the Houston area, we generated complete assemblies of *K. pneumoniae*
124 *sensu stricto* recovered from patients enrolled in the CRACKLE-2 cohort in Houston and other
125 sites in the United States. We assessed potential intra- and inter-clade transmission of vectors
126 responsible for carbapenem resistance between CG258 and CG307, their respective correlated

127 gene content, and their association with clinical outcomes in patients colonized or infected with
128 *CRKp*.

129 **Methods**

130 **Study design**

131 Characterization of patients and isolates was based on the CRACKLE-2 study(3), a prospective,
132 multicenter observational cohort study performed in 49 hospitals across the continental United
133 States. This study focused on patients and their isolates recruited in Houston, TX. A total of 160
134 CRE isolates were collected from 10 hospital sites within the Houston, TX metropolitan area
135 from May 2017 to December 2017. A total of 95/160 CRE (59.4%) were identified as belonging
136 to the *K. pneumoniae* species complex (KpSC) and were subjected to whole genome sequencing.
137 The KpSC is comprised of 7 similar phylogroups (~98-99% average nucleotide identity)
138 including *K. pneumoniae sensu stricto* (Kp1; n = 94) and *K. pneumoniae quasipneumoniae*
139 subsp. *quasipneumoniae* (Kp2; n = 1), which were both found in our study (5, 16). Additionally,
140 we included all other CG307 isolates identified outside of the Houston metropolitan area (n=12)
141 from the CRACKLE-2 study (3), along with 12 geographically matched patients
142 infected/colonized with CG258 isolates for purposes of comparing genomic and population
143 structure differences.

144 **Whole genome sequencing**

145 Isolate culture, genomic DNA extraction, short-read sequencing library preparation, and Illumina
146 short-read sequencing have been described previously (3). All isolates identified as *CRKp* in our
147 sampling frame were subjected to Oxford Nanopore Technologies (ONT) long-read sequencing

148 using the SQK-RBK004 library preparation kit and sequenced on an Oxford Nanopore GridION
149 X5 (Oxford, UK). MinKNOW-v3.0.13 software was used for fast5 generation with subsequent
150 GPU-enabled base-calling and read filtering (minimum length of 1000 bp; Phred score \geq Q7)
151 performed with Guppy-v3.2.2 software. Raw ONT fastq reads were trimmed and de-multiplexed
152 with qcat-v1.1.0 (nanoporetech, GitHub: <https://github.com/nanoporetech/qcat>).

153 **Consensus hybrid bacterial genome assembly pipeline**

154 A customized python script was used for short- and long-read hybrid genome assemblies
155 (Shropshire, W GitHub: https://github.com/wshropshire/flye_hybrid_assembly_pipeline).
156 Briefly, raw assemblies were created with Flye-v2.7 (17). Raw assemblies then underwent a
157 series of error correction steps using first an iterative long-read polish step with Racon-v1.4.5
158 (18) followed by Medaka-v0.11.5 (nanoporetech GitHub:
159 <https://github.com/nanoporetech/medaka>). The consensus medaka assembly then underwent a
160 series of Racon short-read polishing steps with a final error correction step using a modified
161 python script (powerpak GitHub: [https://github.com/powerpak/pathogendb-](https://github.com/powerpak/pathogendb-pipeline/tree/master/scripts)
162 [pipeline/tree/master/scripts](https://github.com/powerpak/pathogendb-pipeline/tree/master/scripts)) that fixes regions with low, short-read coverage. Fragmented
163 assemblies were re-assembled with Unicycler-v0.4.6 (19) and compared with Flye assemblies for
164 accuracy and contiguity. Each assembly was manually curated using the Integrative Genomics
165 Viewer (IGV-v2.8.0) to visually inspect contiguity and accuracy of assemblies using both short-
166 read and long-read alignments (20-22). Further quality control with additional preliminary results
167 were generated using a customized python script (Shropshire, W GitHub:
168 https://github.com/wshropshire/QA_QC_tool).

169 Genome completeness and contamination data were assessed using BUSCO.v4 (23) and
170 CheckM-v1.1.2 (24). Genome completeness, as defined by proportion of lineage specific,
171 colocalized marker gene sets in *Enterobacteriales* (24), was greater than 98% for the entire set of
172 119 KpSC isolates. Genome contamination as defined by multiple copies of these
173 aforementioned marker gene sets (24) was less than 4% for all isolates. These estimates were
174 within the mean absolute error of completeness and contamination using lineage specific sets
175 with all isolates meeting the designation of near complete genomes (24). Assembly metrics are
176 shown in Additional file 1: Table S1 with their respective BioSample Accession and ARLG
177 identification numbers.

178 **Molecular and genomic characterization**

179 Genome annotation was performed using Prokka-v1.14.5 (25). Capsule typing (26, 27), multi-
180 locus sequence typing (MLST), virulence factor (28, 29), and antimicrobial factor quantification
181 was completed using Kleborate-v1.0.0 (30). Clonal groups were defined as similarly related
182 isolates that may only differ by one of seven MLST housekeeping gene alleles as identified by
183 the Pasteur Institute using their BIGSdb (<https://bigsd.bpasteur.fr/klebsiella/klebsiella.html>).
184 Kleborate virulence scores are reported from 0 to 5, as follows: 0, negative for yersiniabactin
185 (*ybt*), colibactin (*clb*), and aerobactin (*iuc*); 1, yersiniabactin only; 2, colibactin with or without
186 yersiniabactin; 3, aerobactin only; 4, aerobactin with yersiniabactin; 5, all three virulence
187 determinants. Kleborate resistance scores range from 0 to 3 with the following definitions: 0, no
188 ESBL, no carbapenemase; 1, ESBL, no carbapenemase; 2, carbapenemase positive without
189 colistin resistance; 3, carbapenemase with colistin resistance. The ABRicate-v0.9.8 tool
190 (Seemann, T GitHub: <https://github.com/tseemann/abricate>) was used in parallel with Kleborate

191 to query the Comprehensive Antibiotic Resistance Database (CARD) (31) and PlasmidFinder
192 (32) databases to characterize antibiotic resistant and plasmid determinants, respectively
193 (Accessed 2020-06-17). A summary of the Kleborate output can be found in Additional file 1:
194 Table S2. A matrix of all *in silico* PCR-based replicon typing found with PlasmidFinder is
195 included in Additional file 1: Table S3.

196 **Pangenome analyses**

197 Panaroo-v1.2.2 (33) was used to generate a pangenome profile from the 118 gff files generated
198 from Prokka-v1.14.5 (25) using the ‘sensitive’ clean-mode for gene contamination filtering.
199 Three reference isolates were included: NJST258_1 (GenBank Accession #:
200 GCA_000598005.1), NJST258_2 (GenBank Accession #: GCA_000597905.1), and KPN11
201 (GenBank Accession #: GCA_002148835.1). Isolate C719 was not included in pan-genome
202 analysis since it is a member of the *K. quasipneumoniae* subsp. *quasipneumoniae* (Kp2)
203 phylogroup (34). Clusters of orthologous gene groups present in greater than $\geq 99\%$ (n=3908) of
204 our total group were aligned using MAFFT-v7.470 (35) to create a core gene alignment. Snp-
205 dists (Seemann, T snp-dists <https://github.com/tseemann/snp-dists>) was used to create a pairwise
206 SNP distance matrix from the core gene alignment. Median nucleotide divergence of core genes
207 analyzed was calculated by taking median pairwise SNP differences and dividing by total length
208 of the core gene alignment minus ambiguous characters and INDELS (3,768,044 bp).

209 IQ-TREE-v2.0.6 (36) was used to create a ML phylogeny inferred tree using the core gene
210 alignment in order to determine population structure. ModelFinder (37) was used to determine
211 the best model fit given our data, which was a GTR substitution model with a rate heterogeneity

212 ‘FreeRate’ model using 3 categories. We performed non-parametric bootstrapping (n = 1,000
213 replicates) and implemented transfer bootstrap expectation (TBE) (38) to create branch bootstrap
214 support values for our final trees. Hierarchical population structure was investigated using the
215 core gene alignment with rhierBAPS-v1.1.3 (39). Tree visualization output was achieved using
216 iTOL (40).

217 A Jaccard distance matrix was created using the gene presence/absence (n=13049) matrix from
218 the pan-genome analysis with the CRAN package “Philentropy” (41). The partitioning around
219 medoid (PAM) algorithm was used with varying cluster sizes (k =1, k = 5) to determine cluster
220 assignment using the CRAN package “cluster” (42). We used the PANINI tool (43) that utilizes
221 the unsupervised clustering t-Distributed Stochastic Neighbor Embedding (t-SNE) method with
222 the Barnes-Hut algorithm to determine how the accessory genome clusters into groups. A
223 principal component analysis (PCA) was performed using the base R ‘prcomp()’ function. The
224 pan-genome reference fasta file generated by Panaroo was functionally annotated for the purpose
225 of observing orthology relationships using EggNOG-v.5 (44, 45). CG307 genome comparisons
226 were generated using the CGViewer Comparison Tool (46). Phage content for representative
227 strains were characterized using PHASTER (47, 48). Data visualization for all analysis
228 performed in R was generated with ggplot2 (49).

229 **Core SNP phylogenies**

230 A core SNP phylogeny was conducted using C268 (CG258) and C246 (CG307) as a reference
231 for short-read alignment using the ‘snippy-multi’ wrapper tool in Snippy-v4.6.0 (Seemann, T
232 GitHub: <https://github.com/tseemann/snippy>) for Houston-only isolates. Similarly, a core SNP

233 phylogeny with CG307 isolates collected from NCBI was performed using C234 as a reference.
234 For SRA only submissions (15), SRA files were retrieved using sratools-v2.10.9 and assembled
235 using SPAdes-v3.14.0. Quality control on assemblies (*e.g.* ambiguous bases, incorrect genome
236 size, contamination) was performed using Kleborate-v2.0.1. Recombination regions were
237 masked using Gubbins-v2.3.4 (50). Subsequently, the filtered alignment file was used as an input
238 to infer a core SNP, maximum-likelihood phylogeny using IQ-TREE-v2.0.6 (36).

239 **Plasmidome characterization**

240 *In silico* plasmid typing and characterization was performed using the MOB-suite, MOB-typer
241 tool (51). Details on all 424 extrachromosomal contigs identified using MOB-typer tool,
242 including replication initiation protein, relaxase, mate-pair formation, and host range prediction
243 are included in Additional file 1: Table S4. We created a sketch representation of the
244 approximate plasmid sequence distances using the MinHash technique with the Mash toolkit (52)
245 at both the isolate ($n = 119$) and individual plasmid level. For plasmid type comparisons,
246 plasmids below 25 kbp, mostly ColE1-like plasmids, were excluded from analysis due to large
247 differences when compared to larger (> 25 kbp) size plasmids. The distance matrices were then
248 used to generate a heatmap and dendrogram using the heatmap.2 (talgalili, GitHub:
249 <https://github.com/talgalili/gplots>) R package. The dendrogram was created through
250 agglomerative hierarchical clustering using an ‘average’ linkage.

251 **Conjugation transfer assays**

252 Four isolates with plasmids of interest based on plasmidome analysis were included in
253 conjugation transfer assays using a modified protocol (53). Details for the particular plasmids

254 studied can be found in Additional file 1: Table S5. Easyfig was used to compare plasmid
255 structures (54). Donors and a sodium azide (NaN₃)-resistant *E. coli* strain J53 were grown up
256 overnight in TSB supplemented with 2 µg/mL ertapenem or 10 µg/mL gentamicin for plasmid
257 selection and 150 µg/mL NaN₃ for counter-selection at 37°C with mild agitation. Overnight
258 cultures were washed in 0.9% NaCl 2X and then sub-cultured into fresh TSB at a 1:100 dilution
259 and incubated at 37°C until mid-log phase (~0.6 OD₆₀₀). Broth mating was performed with 1:10
260 donor-to-recipient ratios with TSB overnight at 37°C for 20 hours. TSA plates supplemented
261 with 2 µg/mL ertapenem or 10 µg/mL gentamicin and 150 µg/mL NaN₃ were used to select for
262 transconjugants. Conjugation transfer frequency was enumerated by calculating the ratio of
263 CFU/ml in transconjugants over the CFU/ml in the donor plates respectively. The limit of
264 detection was calculated by taking the minimum CFU threshold detected factoring in dilution
265 factor (50 CFU/mL) and dividing by donor frequency. We used a PCR protocol to check for the
266 positive identification of transconjugants screening for *bla*_{KPC-2}, *aacA4*, *E. coli* J53 (*rpoB* gene),
267 as well as plasmids of interest with primers listed in Additional file 1: Table S6.

268 **Clinical data outcomes assessed using desirability of ordinal outcome ranking (DOOR)** 269 **analysis**

270 The Houston-based CG258 (n=27) isolates and CG307 (n=32) isolates were included in an
271 inverse probability weighted (IPW)-adjusted Desirability of Ordinal Outcome Ranking (DOOR)
272 analysis (55) in which composite patient level outcomes were compared. Three detrimental
273 outcomes (no clinical response, unsuccessful discharge, adverse event) were used to create the
274 ordinal DOOR outcome assessed 30-days after culture, as described before (3). Briefly, the
275 outcomes were defined as follows: (1) ‘clinical response’ was an improvement in symptoms with

276 no additional antibiotic course that has *in vitro* activity against first positive culture and no
277 subsequent relapse; (2) ‘unsuccessful discharge’ was post-culture stay \geq 30 days or readmission
278 within 30 days; (3) patients had an ‘adverse event’ if subsequent *Clostridioides difficile* infection
279 or post-culture renal failure occurred. The most favorable outcome was ‘(1) alive without events’
280 whereas the worst outcome was (4) death; intermediate levels were (2): alive with one event and
281 (3): alive with 2 or 3 events. An IPW-adjusted DOOR probability estimate of composite
282 outcomes between patients in each of the two clonal groups was assessed, with a 50% probability
283 estimate indicating comparable outcomes. A DOOR probability estimate greater than 50% with a
284 95% confidence interval above 50% indicates, with statistical significance, a more favorable
285 outcome for one randomly selected member of a group compared to a randomly selected member
286 of another group. Covariates that were included into the weights were age, Charlson comorbidity
287 index, and origin of patient admission. Non-parametric bootstrap methods (n=4000) were used to
288 estimate 95% confidence intervals.

289 **Statistics**

290 Group level distributions of continuous variables were evaluated using one-way ANOVA test or
291 Kruskal-Wallis rank-sum tests contingent on assumptions based on the data distributions. *Post-*
292 *hoc* tests for continuous variables with significant ANOVA p-values were accomplished using
293 the Tukey’s honest significance test or the Dunn test using the “FDR” method to control for
294 multiple comparisons. Wilcoxon rank-sum test was used to determine distribution differences of
295 continuous variables across two groups. Distributions of categorical data were evaluated using
296 Pearson Chi Square or Fisher’s Exact tests, dependent on cell counts. All statistical analysis was
297 performed with R-v4.0.0 software.

298 **Results**

299 **Molecular epidemiological features of CG258 and CG307 circulating in same geographical** 300 **area reveal distinct virulence and antimicrobial resistance gene content**

301 The majority of isolates identified as CRKp belonged to the taxa *K. pneumoniae sensu stricto*
302 (94/95; 98.9%), with the exception of one isolate (C719, identified as *K. quasipneumoniae* subsp.
303 *quasipneumoniae*). The predominant CRKp sequence types identified in the Houston cohort were
304 CG258 (37/95; 38.9%) and CG307 (35/95; 36.8%). The remaining isolates belonged to CG15
305 (n=5), CG20 (n=4), CG147 (n=4) and a mixture of other sequence types (n = 10) (Fig. 1). There
306 were no observed correlations between clonal group and hospital location across the Houston
307 metropolitan area ($p = 0.8$), suggesting each site had a similar distribution to the overall
308 circulation of sequence types in this hospital system (Additional file 2: Fig. S1).

309 Molecular epidemiological features of the Houston *K. pneumoniae* isolates are shown in Table 1.
310 The median genome size of isolates belonging to CG307 was smaller than CG258 and other
311 heterogeneous sequence types, although there were no significant differences in chromosome
312 sizes between the three CGs. The smaller genome size of CG307 was due to a smaller number of
313 plasmids as compared to CG258 or other CGs (Table 1). The mean number of acquired
314 antimicrobial resistance (AMR) genes per genome, *i.e.* the average number of non-intrinsic
315 AMR genes found per CRKp isolate, was 7.8 ± 5.0 genes (Additional file 2: Fig. 2A). The
316 median number of acquired AMR genes stratified by group was similar between CG258 (5; IQR
317 = 6), CG307 (7; IQR=5), and other CGs (9; IQR=10.5). We did not find a statistically significant
318 difference across these subsets in the numbers of genes encoding AMR determinants of different
319 classes (*i.e.*, number of antibiotic classes with at least one resistance determinant per genome)

320 (Additional file 2: Fig. 2B). We also analyzed AMR and virulence determinants using the
321 Kleborate composite resistance scoring metric (30) along with the categorical virulence score
322 (see materials and methods). We found no statistically significant difference in Kleborate
323 resistance scores between CG258 and CG307 (adj. p-value = 0.3). However, CG258 isolates had
324 a statistically significant higher resistance score than the group of other heterogenous sequence
325 types (adjusted p-value = 0.007). The Kleborate composite virulence scores in Table 1 reflect
326 that the Houston CG307 isolates lacked genes encoding siderophores (e.g., yersiniabactin,
327 salmochelin, aerobactin), the genotoxin colibactin gene cluster and hypermucoidity genes (*rmpA*
328 and *rmpA2*), which are commonly found virulence determinants in hypervirulent lineages of *K.*
329 *pneumoniae sensu stricto* (28, 29).

330 Multiple conjugative elements (ICE*Kp*) carrying virulence factors integrated in the chromosome
331 of *K. pneumoniae* lineages have been previously described (28). These mobile genetic elements
332 largely contribute to hypervirulent, high-risk strains of *K. pneumoniae* commonly observed in
333 Asian countries (5). Interestingly, 35.1% (13/37) of CG258 Houston, TX isolates carried a
334 chromosomally inserted ICE*Kp* with an associated yersiniabactin gene (*ybt*) cluster. The ICE*Kp*
335 in most of these CG258 isolates harbored an ICE*Kp*10 – *ybt*17 sequence type with the exception
336 of one Houston CG258 isolate (C592) that carried a novel *ybt* sequence type. All Houston
337 CG258 isolates harboring ICE*Kp* also contained the ICE*Kp*-associated genotoxin and colibactin
338 gene cluster from the *clb3* lineage. In contrast, all Houston CG307 isolates lacked ICE*Kp*
339 integration. Only one CG307 isolate in the non-Houston isolates (C4693 recovered from a
340 patient in Georgia) harbored a chromosomal ICE*Kp*, which belongs to the ICE*Kp*12 lineage and
341 encodes *ybt*16 sequence type. An important epidemiological observation relating to the

342 population structure of *K. pneumoniae* is the rare convergence of multidrug-resistant (MDR)
343 high-risk lineages with hypervirulent clones (5, 16). We identified two *CRKp* isolates, C308
344 (ST23) and C346 (ST231), that harbored aerobactin-encoding *iuc* genes along with *bla*_{KPC-2} and
345 *bla*_{OXA-232}, suggesting that the convergence of MDR and potentially hypervirulent clones is
346 occurring in our study population.

347 **The population structure in co-circulating CG258 and CG307 indicates nested subgroups**
348 **within each lineage**

349 The pangenome of the full cohort (n=122), using 94 *CRKp* Houston isolates with 12 CG307 and
350 12 CG258 isolates collected from other CRACKLE-2 US hospital sites (n=48) plus three
351 references (see material and methods), consisted of 13,049 genes, of which 3,908 (29.9%) made
352 up the core genome, defined as gene groups included in $\geq 99\%$ of the isolate cohort. The overall
353 median nucleotide divergence, a measure of genetic variation within a population based on
354 normalized polymorphism counts, was 0.59%, suggesting that less than 1% of the core genome
355 nucleotide sites were variant sites. This nucleotide diversity is comparable to previously shown
356 measures of genetic variation within the *K. pneumoniae sensu stricto* phylogroup based on core
357 gene alignment (16). Bayesian hierarchical modeling was used to group individual taxa into
358 clusters based on core gene alignment. The population split into 6 hierarchical levels
359 corresponding to five multidrug-resistant clonal groups (CG15, CG20, CG147, CG258, CG307)
360 and a mixture of other heterogeneous sequence types (Fig. 1).

361 To dissect lineage specific population structures, recombination free, reference-based core SNP
362 maximum-likelihood phylogenetic trees were created for both CG258 and CG307 (Fig. 2). The

363 inter-group median nucleotide divergence of CG258 and CG307 was 0.6%, which was
364 comparable to overall divergence. The intra-group median nucleotide divergence calculated for
365 the CG258 group was 0.013%, a core genome nucleotide diversity expected for a clonal group
366 showing a more homogenous core genome at the clonal group level, compared to the overall
367 species level. We identified two clades within the CG258 lineage (Fig. 2A), split largely by the
368 capsule synthesis locus (*cps*), as previously described (7, 56). Clade 1 (*wzi* 29/KL106) and clade
369 2 (*wzi* 154/KL107) encompassed 45% and 51% of CG258 *K. pneumoniae* isolates, respectively.
370 The remaining 4% of CG258 isolates had unique capsular synthesis loci and/or a large *ISKpn26*
371 mediated deletion in this region (a region known to have a high rate of recombination). There
372 were nested population structures within each clade that segregated by geographical site
373 (Houston vs. other United States CRACKLE-2 sites), with a clearer delineation within clade 1.
374 There was a strong association of isolates harboring *ICEKp10* (primarily the *ybt17* lineage) with
375 clade 2 isolates (18/25; 72%) not observed in clade 1 isolates (p-value = 5e-6).

376 The CG307 group (Fig. 2B) was less divergent compared to CG258, with a median nucleotide
377 divergence of 0.004%. There was a marked geographical split of the CG307 group, correlating
378 with the predicted four hierarchical clusters within the core population structure. A majority of
379 CG307 isolates had the same K and O loci (*wzi173* allele associated with the KL102 locus and
380 the O2v1 [3/47] or O2v2 [33/47] loci, respectively), with the exception of one isolate (C291)
381 which had a 28,813-bp *ISKpn26* associated deletion in the *cps* locus.

382 To determine the overall population structure of CG307 isolates in the Houston region, relative
383 to historical isolates detected globally, a reference-based alignment maximum likelihood inferred

384 phylogeny was generated with CG307 isolates (n=798), using C234 (the first CG307 isolate in
385 the Houston population), as a reference (Fig. 3). Four hierarchical population structures were
386 detected, with a prominent distinction between three Houston-based ST307 clades (clade I, III,
387 IV) and the worldwide disseminated CG307 clade (clade II) (Fig. 3). Houston-based Clade III
388 isolates shared a common ancestor with Clade IV isolates not shared with the distinct Clade I and
389 Clade II isolates. Thus, phylogenetic reconstruction suggests that three particular lineages of
390 CG307 (clades I, III, and IV) distinct from CG307 found in other parts of the world (Clade II),
391 are currently circulating in Houston hospitals.

392 **Dissection of the accessory genome suggests independent evolution and limited horizontal**
393 **gene transfer between CG307 and CG258 lineages**

394 We sought to determine the extent of accessory genome sharing within our *CRKp* group as a
395 measure of potential interclade horizontal gene transfer of antimicrobial resistance and virulence
396 determinants. We took this approach to understand dynamics of circulation of these genes
397 between high-risk clones that might explain how they co-circulate in the Houston area. Thus,
398 using the full cohort described in the previous section, we sought to determine the geographical
399 clustering of the accessory genomes of all *K. pneumoniae* isolates, including genes encoding
400 carbapenemases. Interestingly, the clustering analysis indicated a distinct separation of the
401 CG258 accessory genome from the rest of the isolates (Fig. 4A and 4B), suggesting that CG258
402 does not share its accessory genome with other lineages. Fig. 4A shows that, with the exception
403 of one Georgia isolate (C4688), CG307 isolates from Houston cluster together and are distinct
404 from non-Houston CG307. In contrast to the unique accessory genome components in CG307

405 that segregated by region, we were unable to identify geographical clustering of accessory
406 genome of CG258 isolates.

407 We then identified the minimized genomic distance between each isolate to determine which
408 isolates were more likely to share similar accessory genome content based on their predicted
409 cluster assignment. Fig. 4B shows that when cluster groups were identified by sequence
410 similarity (pairwise binary distances between the 122 isolates), there was a split in CG258 that
411 largely segregated by *cps*-associated clades (cluster 1 vs cluster 2), with four exceptions (C293,
412 C295, C259, and C4688). CG307 isolates shared a cluster assignment (cluster 3, Fig. 4B) with
413 ten other isolates belonging to non-CG307. Furthermore, CG307 accessory genomes appeared to
414 cluster with CG147 isolates in our cohort. Principal component analysis (PCA) of the accessory
415 genome indicated that 90.7% of the variance in the dataset could be explained in the first two
416 components of the accessory genome with noted separation of CG258 from CG307, as well as
417 the other clonal groups (Additional file 3: Fig. S3) observed in two-dimensional analysis, further
418 supporting our previous clustering results. Overall, our data suggest that the accessory genomes
419 of CG258 and CG307 diverged with a clear separation between CG258 and other clonal
420 lineages.

421 To further support the divergence of CG258 from CG307 and lack of genomic sharing, we
422 analyzed a subset of the accessory genome excluding low ($\leq 5\%$) and high ($\geq 95\%$) frequency
423 gene groups that are less indicative of horizontal gene transfer within the full cohort and
424 determined distribution differences by cluster of orthologous genes (COGs) functional categories
425 (Additional file 1: Table S7). Fig. 4C shows the overall distribution of accessory genome content

426 annotated by functional group across all clonal groups found. When focusing on COG functional
427 group proportions of CG258 vs CG307 isolates, we found statistically significant differences in
428 relative frequency proportions of each respective COG functional group with all but 5 of the 18
429 characterized COG functional groups (Fig. 4D). In contrast, there were fewer statistically
430 significant differences observed in the proportion of COG functional groups within the accessory
431 genomes for both CG258 and CG307 compared to each respective other clonal group found in
432 the cohort (Additional file 2: Fig. S4). These findings support the notion that there are accessory
433 genome functional differences between CG307 and CG258 and there have been independent
434 adaptive responses to potential selective pressures.

435 The largest statistically significant differences in COG functional groups between CG258 and
436 CG307 were in predicted carbohydrate metabolism and transport mechanisms (G), cell
437 membrane structure/biosynthesis (M), and replication/recombination/repair (L) genes (Fig. 3D).
438 The larger proportion of replication, recombination, and repair genes (L) in CG258 is likely due
439 to a higher number of plasmids observed in CG258 compared to CG307 isolates. Noted
440 differences include a previously described chromosomal, 13 kb π -fimbriae gene cluster (12),
441 conserved in all CG307 isolates ($n = 48$) and absent from all CG258 ($n = 51$) (adj. p-value = $8e$ -
442 33) (Additional file 2: Fig. S5). The aforementioned fimbrial gene cluster was also present in all
443 four CG147 isolates. A second, previously described (12), chromosomal capsular synthesis
444 cluster with 12 genes (Cp2) was present in all 48 CG307 isolates and absent from all others (adj.
445 p-value = $9e$ -34) (Additional file 2: Fig. S5). Conversely, there was a carbohydrate metabolism
446 operon (designated *ydjEFGHIJ*) exclusively found on all CG258 and CG147 isolates, and absent
447 in the CG307 isolates (adjusted. $p = 5e$ -34). Carriage of unique phages between CG307 and

448 CG258 was a primary driver of accessory genome differences. Indeed, three intact phages
449 detected in CG307 were absent in CG258 (Additional file 2: Fig. S5). These results collectively
450 indicate that CG258 and CG307 each contain highly conserved and distinct accessory genomes,
451 which are likely driving independent endemic spread of each lineage in the Houston region.

452 **Carriage of chromosomal *bla*_{CTX-M-15} is the major antimicrobial resistance determinant of**
453 **CG307 in the Houston area with evidence of independent acquisitions of *bla*_{KPC-2}**

454 Table 2 provides an overview of the antimicrobial resistance profile of the CRKp Houston
455 isolates. The number of isolates carrying a carbapenemase gene was 84/95 (88.4%). The majority
456 of the isolates harboring carbapenemase genes were *bla*_{KPC-2} carriers (77/95; 81.1%), followed by
457 *bla*_{KPC-3} (4/95; 4.2%), *bla*_{NDM-1} (2/95; 2.1%) and *bla*_{OXA-232} (1/95; 1.1%). Most *bla*_{KPC} carriage
458 occurred on the Tn4401a isoform (94%; Additional file 1: Table S8). CG258 isolates harbored
459 either *bla*_{KPC-2} (35/37; 94.6%) or *bla*_{KPC-3} (2/37; 5.41 %) with the majority on pKpQIL plasmids
460 (27/37; 73%), whereas most CG307 isolates (31/35; 88.6%) carried *bla*_{KPC-2} on different vectors,
461 with one isolate (C678) carrying two *bla*_{KPC-2} copies, one on the chromosome and the other on a
462 FIIK/FIB(pQIL) plasmid. The distribution of *bla*_{KPC}-containing plasmids was more diverse in
463 CG307, with evidence of multiple recombination events in plasmids carried by CG307 vs CG258
464 isolates (Fig. 1), in particular with different F-type and R-type plasmids. Interestingly, we could
465 identify a cluster of six CG307 isolates (average 40 SNPs differences) that harbored Tn4401a in
466 the same chromosomal context (Fig. 1) originating from five different Houston regional
467 hospitals.

468 A characteristic feature of the Houston CG307 is that all isolates harbored more than one copy of
469 *bla*_{CTX-M-15} (2 [n=25], 3 [n=9] and 4 [n=1]) (Table 2 and Fig. 2B). *bla*_{CTX-M-15} was primarily
470 located in the chromosome, with 2-3 copies per genome in relatively similar genomic contexts.
471 Only 3 Houston CG307 isolates had plasmids (pC251_1, pC258_1, pC291_1) harboring *bla*_{CTX-}
472 _{M-15}. All 3 plasmids were F-type pKPN3-like plasmids, which have been associated with CG307
473 isolates in other geographical locales (10, 11). In contrast to CG307, only 2/37 (5.4%) CG258
474 isolates harbored *bla*_{CTX-M-15}, with the two isolates having the gene on distinct pKPN3-like
475 plasmids (pC268_1 and pC608_2). The *bla*_{SHV-12} variant was the most common ESBL gene
476 carried by CG258.

477 Except from a CG307 Georgia isolate (C862) which shared similar genomic characteristics with
478 CG307 from Houston, all other CRACKLE-2 CG307 recovered outside of Houston exhibited
479 distinct accessory genome features (Fig. 2B), supported by previous phylogenetic analyses (see
480 above). Indeed, a majority of non-Houston CG307 (10/12, 83%) harbored a pKPN3-like plasmid
481 with 6 having *bla*_{CTX-M-15} as part of an *ISEcp1* element. Furthermore, 3 of the 8 CG307 non-
482 Houston isolates carried *bla*_{KPC} on non-Tn4401a transposons (compared to all Houston isolates,
483 which carried *bla*_{KPC} on Tn4401a; Additional file: Table S8). Additionally, non-Houston
484 CG307s harbored A/C-type plasmids (n=2) and carrying *bla*_{KPC}, a feature absent in Houston
485 isolates (Fig. 5). These results support that a unique and distinct epidemic lineage of CG307 is
486 currently circulating in tertiary care hospitals in Houston, TX.

487 **CG258 and CG307 isolates harbor unique plasmid content**

488 To determine the full complement of plasmid vectors assembled in our *CRKp* cohort, we
489 characterized the full plasmid content (i.e., the plasmidome) to assess potential clustering and
490 sharing of plasmids by clonal group. The plasmidome of our *CRKp* isolates was highly diverse
491 (Fig. 5) with an average number of plasmid structures of 3.5 per isolate (min 1; max 7). Plasmid
492 content clustered by core-defined clonal groups (Fig. 5A) with a majority of CG258 isolates
493 clustering within their own distinct group (Fig. 5A, top right). In particular, there were three
494 plasmid-types associated with the CG258 lineage, including X3, FII(K)/FIB(K) and
495 FII(K)/FIB(pQIL) plasmids (Fig. 5B). There was a particular rep-3 family replication initiator
496 protein (52/415; 12.5%) associated with a plasmid (rep_cluster_1418; Additional file 1: Table
497 S4) found in nearly all Houston CG307 isolates (31/35; 88.8%). These CG307 rep-3 family
498 plasmids (herein referred to as pCG307_HTX) primarily clustered with F-type and R-type
499 plasmids (Fig. 5B). 30/52 (57.7%) pCG307_HTX plasmids were predicted to be non-
500 mobilizable, with the rest (22/52; 42.3%) predicted to be conjugative and/or mobilizable,
501 harboring *tra* operons and/or *mob* encoding genes with essential *oriT* sites. Importantly, 10/31
502 (32.3%) pCG307_HTX plasmids carried Tn4401a-*bla*_{KPC} (Fig. 5B), suggesting that this plasmid
503 may have been important for carbapenemase dissemination. Collectively, our results indicate that
504 the CG258 plasmidome is conserved and largely segregated from other co-circulating *CRKp*
505 isolates, including CG307, in agreement with the pan-genome analyses.

506 **The novel pCG307_HTX plasmid carrying Tn4401a conjugates at similar rates compared**
507 **to CG258 pKpQIL plasmid**

508 To evaluate the potential for horizontal transfer of carbapenemase genes, we chose 4 plasmid
509 candidates of interest based on plasmidome results, with three belonging to CG307 and one to
510 CG258. We assessed relative conjugation transfer frequencies of two *bla*_{KPC-2} carrying plasmids
511 with the novel rep-3 family *repA* gene (*i.e.*, pCG307_HTX plasmids, one each predicted to be
512 conjugative [pC299_2] or not conjugative [pC711_1], respectively). Conjugation efficiencies
513 were compared using a comparable size pKpQIL plasmid (pC344_1, CG258 vs pC299_2,
514 CG307) that shared a similar *tra* operon and cargo gene region (Additional file 2: Fig. S6).
515 Additionally, we chose a pKPN3-307_typeA-like plasmid (pC763_2) primarily found in our
516 non-Houston CG307 isolates to compare its conjugative frequency with the aforementioned F-
517 type plasmids (Additional file 2: Fig. S6). Three of the four F-type plasmids had detectable,
518 positive transconjugants in a proportion of conjugation transfer assay experiments (Additional
519 file 2: Fig. S7), with varying efficiencies. pKpQIL (pC344_1) and rep-3 family multi-replicon F-
520 type (pC299_2; pCG307_HTX) plasmids had comparable, low average transfer frequencies of
521 4.1×10^{-7} and 2.9×10^{-6} , respectively. The pKPN_3_typeA plasmid associated F-type plasmid
522 had a greater transfer frequency (6.3×10^{-5}). However, this did not reach a statistically
523 significant difference ($p = 0.06$). As expected through *in silico* prediction, pC711_1 yielded no
524 transconjugants in any of the three conjugation transfer assays. Overall, our conjugation
525 experiments validated *in silico* predictions of mobilization and confirmed potential broad host
526 range transmission of the novel pCG307_HTX plasmid associated with the Houston CG307.

527 **Patients with CG307 colonization or infection may have more favorable outcomes**
528 **compared to those with CG258**

529 Clinical epidemiological features stratified by CG for the Houston, TX isolates are presented in
530 Table 3. The crude 30-day mortality for the full Houston cohort (n=73) was 17.8%; (13/73 [95%
531 CI: 7.8 – 22.6%]). When comparing clinical features across the CG258 and CG307 groups,
532 patients with CG258 exhibited a statistically significant higher 30-day mortality compared with
533 those infected/colonized with CG307, albeit with a small number of events. Patients with CG307
534 infection/colonization exhibited a higher proportion of samples isolated from urine (65.6%)
535 compared to CG258 (37.0%), but this association did not reach statistical significance (p=0.068).
536 Conversely, patients with CG258 infection/colonization had a higher proportion of isolates from
537 blood (14.8% vs 0%) and respiratory cultures (25.9% vs 12.5%) compared to the CG307 patient
538 group.

539 To further investigate differences in clinical outcomes for patients with CG307 vs CG258, we
540 calculated an inverse probability weighted (IPW) Desirability of Ordinal Outcome Ranking
541 (DOOR) outcome (55) at 30-days (see Materials and Methods) for the Houston, TX cohort. The
542 IPW-adjusted DOOR probability estimate was 64% (95% CI: 48-79%). This represents the
543 probability that a randomly selected CG307 patient would have a better outcome than a
544 randomly selected CG258 patient, and suggests that patients with CG307 colonization or
545 infection trended towards better overall outcomes following adjustment for potential
546 confounding that may arise in an observational study (Table 4).

547 **Discussion**

548 Although *K. pneumoniae* CG258 has been considered the major genetic lineage responsible for
549 endemicity of carbapenem resistance, in recent years, a new lineage, designated *K. pneumoniae*
550 CG307, has emerged (11-13). Since the first report of CG307 in the Netherlands in 2008, it has
551 been identified in different parts of the world, including Colombia (57), Italy (58, 59), South
552 Africa (60, 61), Pakistan (62) and South Korea (63), among others. Interestingly, the first
553 detection of CG307 in the United States occurred in Houston, TX in 2013 (64) and was
554 subsequently followed by an outbreak in a large, Houston hospital system (15). A more recent
555 study assessing the clinical and genomic epidemiology of carbapenem-resistant *Enterobacterales*
556 in the United States (3), showed that Houston was the first major city in the US where
557 carbapenem-resistant *K. pneumoniae* CG307 seemed to have established endemicity along with
558 isolates belonging to CG258. Furthermore, a recent study suggests that CG307 may be spreading
559 to other municipalities in south Texas and co-circulating with CG258 (65). The concomitant
560 circulation of these major clones provided an opportunity to dissect their dynamics of
561 dissemination, genetic relationships, and evolution using a pangenomic approach combined with
562 robust clinical data. Our findings suggest that CG258 tends to have a higher median plasmid
563 content with a similar number of AMR determinants found across all *CRKp* isolates. The
564 absence of any known determinants associated with hypervirulent lineages in CG307 suggests
565 that CG258 may have a higher likelihood of causing more adverse infections through the
566 convergence of high-risk multidrug resistant and hypervirulent genotypes in our study
567 population. Of note, this assumption was supported by our DOOR analyses.

568 The most striking finding of our study was that the two main multidrug-resistant *K. pneumoniae*
569 lineages have evolved independently of one another and appear to be disseminating in parallel
570 with limited evidence of inter-clade horizontal gene transfer between them. Moreover, our results
571 support the notion than CG307 plasmids carrying KPC carbapenemases are likely to be shared
572 with other clonal groups, except CG258, amplifying the epidemic of multidrug-resistant
573 organisms in the same geographical area. Partitioning of the accessory genome by COG
574 functional groups indicate large differences in distribution between CG258 and CG307 accessory
575 genome content that are less apparent when comparing each respective clade with other clonal
576 groups. These differences are potentially driven, in part, by CG307 having greater proportion of
577 carbohydrate metabolism and cell membrane synthesis determinants. Unique virulence factors
578 found in our cohort, such as a separate chromosomal capsular synthesis locus (Cp2) shared
579 across CG307 isolates and plasmid-borne glycogen synthesis clusters found on CG307 plasmids
580 have been previously documented in CG307 isolates found in Colombia and Italy (12).

581 Virulence factors such as the filamentous, extracellular organelles and type 1 fimbriae are
582 associated with colonization and infection of the urinary tract in *E. coli* and *K. pneumoniae*
583 (66-69). Interestingly, a unique π -fimbriae gene cluster (12) was strongly associated with CG307
584 and CG147 isolates, with urine as a main source where CG307 were recovered. Furthermore, we
585 found accessory genome intersection between CG307 and CG147 isolates by clustering analysis,
586 with comparable proportions of COG functional groups carried by each group. Indeed, there has
587 been recent evidence of parallel antimicrobial resistance patterns shared between CG307 and
588 CG147 with acquisition of similar F- and R-type plasmids harboring *bla*_{CTX-M-15} along with

589 identical *gyrA* and *parC* mutations conferring quinolone resistance, suggesting a common
590 evolutionary pathway (12).

591 Our study also identified a unique plasmid (designated pCG307_HTX) in CG307 isolates
592 carrying a rep-3 family initiator replication protein with potential for vertical and horizontal
593 transmission based on predicted mobility, as well as positive transconjugants in our conjugative
594 transfer assays. A similar rep-3 family plasmid that recombined with an FII(K) plasmid had been
595 described in a CTX-M-15 associated ST416 *K. pneumoniae* isolate (pKDO1; GenBank accession
596 #: JX424423) (70). We also found that the previously identified FII(K)/FIB(K) plasmid(12),
597 harboring *bla*_{CTX-M-15} associated with worldwide CG307 isolates, had relatively higher
598 conjugative transfer efficiency compared to the Houston pCG307_HTX and CG258 pKpQIL
599 plasmid. This FII(K)/FIB(K) plasmid harboring *bla*_{CTX-M-15} was less prevalent in the Houston
600 CG307 cohort (n=3) where the primary vector of ESBL transmission was stable integration of
601 two copies of a chromosomal *ISEcp1-bla*_{CTX-M-15} transposon. We found that while CG258 may
602 have a greater number of plasmids per genome, plasmidome analyses suggest a greater diversity
603 of unique vectors carrying genes encoding carbapenemases for the CG307 lineage with the
604 potential for sharing across other circulating non-CG258 CRKp isolates in the Houston region.

605 Our clinical data from patients infected/colonized with carbapenem-resistant CG258 vs CG307
606 in Houston, TX suggests that patients harboring CG307 may have more favorable outcomes
607 compared to those with CG258 although our DOOR probability estimate didn't reach statistical
608 significance. Genomic insights provided from our analyses also support CG307 appearing to
609 carry fewer hypervirulence determinants than CG258 isolates. Thus, it is tempting to speculate

610 that the CG307 lineage in our population has evolved as a human colonizer with the propensity
611 to acquire and disseminate antibiotic resistance determinants to other lineages (except CG258),
612 perpetuating and amplifying dissemination of genes coding for carbapenemases. Interestingly,
613 this propensity for disseminating multiple AMR determinants to other clonal groups was noted in
614 a recent outbreak of CG307 in northeast Germany (71). In contrast to our study, they had also
615 found the potential of convergent hypervirulent and multi-drug resistant CG307 isolates due to
616 promiscuous sharing of plasmids carrying multiple hypervirulent and AMR determinants (71).
617 Our epidemiological investigation along with this northeast Germany surveillance study indicate
618 the high potential of horizontal gene transfer along with noted regional variation in accessory
619 genome content across different CG307 clades.

620 There are limitations in our study. Caution should be exercised when inferring differences in
621 clinical outcomes of patients with CG258 vs. CG307 due to inclusion of both infection and
622 colonizing isolates with small sample sizes. Additionally, there may be underlying characteristics
623 in the two respective patient populations that were not accounted for in our DOOR analysis.
624 While generalizability may only apply to the Houston region, additional sampling will be
625 required to determine if these clinical outcome results persist in other regions where CG307 may
626 be circulating. Nonetheless, despite these limitations, the combination of our IPW-DOOR
627 analysis along with our genomic data suggest that such differences in clinical outcomes may be
628 meaningful in our patient population.

629 **Conclusions**

630 In conclusion, our data provide a detailed dissection of a unique phenomenon of parallel
631 epidemics of two high-risk lineages of carbapenemase-producing *K. pneumoniae*, both of which
632 are considered an urgent public health. The genomic and clinical insights presented here are
633 likely to provide novel understanding of the epidemiology of multidrug-resistant *K. pneumoniae*
634 in order to design innovative tools to improve patients' outcomes.

635 **List of Abbreviations**

636 CG = Clonal Group

637 COG = Cluster of Orthologous Genes

638 CRKp = Carbapenem-resistant *Klebsiella pneumoniae*

639 DOOR = Desirability of Ordinal Outcome Ranking

640 ESBL = Extended-spectrum Beta-lactamase

641 IPW = Inverse Probability Weighted

642 PCA = Principal Component Analysis

643 ST = Sequence Type

644 t-SNE = t-Distributed Stochastic Neighbor Embedding

645 **Declarations**

646 **Ethics Approval and Consent to Participate**

647 Original data was collected with the approval of The University of Texas Health Science Center
648 at Houston IRB, the Committee for Protection of Human Subjects (CPHS; Protocol ID: HSC-
649 MS-16-0334; Ethical approval: 5/16/2016), and no further data were collected from these

650 subjects. CRACKLE-2 data collected outside of Houston was approved through the Duke
651 University Health System Institutional Review Board for Clinical Investigations (DUHS IRB;
652 Protocol ID: Pro00071149; Ethical approval: 6/29/2016) with no clinical data reported in this
653 study. All clinical isolates were stripped of identifying information prior to analysis. All clinical
654 data was deidentified upon receipt.

655 **Consent for Publication**

656 Not applicable

657 **Availability of Data and Materials**

658 Short-read and long-read fastq files along with complete assemblies for all *K. pneumoniae*
659 isolates sequenced including isolates previously published (3) are in BioProject PRJNA658369.
660 The supplemental datasets supporting the conclusions of this article are included within the
661 article and its additional files. Additional files supporting the conclusions of this article are
662 available in a Gitlab repository,
663 https://gitlab.com/carmig_dissertations/shropshire_dissertation/crkp_supplemental_files.

664 **Competing Interests**

665 CAA reports **Grants** from NIH, Merck, Memed Diagnostics and Entasis pharmaceuticals.
666 **Royalties** from UpToDate, and **editor's stipend** from American Society for Microbiology.
667 VGF reports **personal consultancy fees** from Novartis, Novadigm, Durata, Debiopharm,
668 Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetrphase, Trius, MedImmune,
669 Bayer, Theravance, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea,

670 Destiny, Amphlphi Biosciences. Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera,
671 Aridis; **Grants** from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance,
672 Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech,
673 Regeneron, Basilea, Janssen, **Royalties** from UpToDate; **Stock options** Valanbio; a **patent**
674 **pending in** sepsis diagnostics; **educational fees** from Green Cross, Cubist, Cerexa, Durata,
675 Theravance, and Debiopharm; and an **editor's stipend** from IDSA.

676 **Funding**

677 Support for this study was provided by the National Institute of Allergy and Infectious Disease
678 (NIAID) K24AI121296, R01AI134637, R01AI148342-01, R21AI143229, P01AI152999-01 to
679 C.A.A., UTHealth Presidential Award, University of Texas System STARS Award, and Texas
680 Medical Center Health Policy Institute Funding Program. B.M.H was supported by the NIAID
681 K01AI148593-01. D.v.D was supported by NIH/NIAID grant R01AI143910. BCF was funded
682 using US Veterans Affairs Merit Review Award 5I01 BX003741. Additionally, part of this work
683 was supported by NIAID of the National Institutes of Health under Award Number
684 UM1AI104681. Disclaimer: The contents are solely the responsibility of the authors and do not
685 necessarily represent the official views of the National Institutes of Health.

686 **Author contributions**

687 W.C.S and A.Q.D.: next generation sequencing (NGS). W.C.S.: comparative genomics analysis
688 and bioinformatics. W.C.S., D.P., and S. I. G.-V.: plasmid experiments and analysis. C.H.,
689 D.V.D., R.B., and B.K. provided and curated clinical data. W.C.S., L.K., M.E., and H.M.:
690 statistical analyses. W.C.S.: original draft preparation. C.A.A., B.M.H., and S.A.S.:

691 Conceptualization, supervision, and original draft preparation. C.A.A.: procured funding for
692 project. All authors contributed to interpretation of results and critical review of manuscript.

693 **Acknowledgements**

694 Not applicable

695 **References**

- 696 1. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global Dissemination of
697 Carbapenemase-Producing *Klebsiella pneumoniae*: Epidemiology, Genetic Context, Treatment
698 Options, and Detection Methods. *Front Microbiol.* 2016;7:895.
- 699 2. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et
700 al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of
701 *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2001;45(4):1151-61.
- 702 3. van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, et al. Molecular
703 and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2):
704 a prospective cohort study. *The Lancet Infectious Diseases.* 2020;20(6):731-41.
- 705 4. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-
706 resistant Enterobacteriaceae in the United States. *Expert Rev Anti Infect Ther.* 2014;12(5):565-
707 80.
- 708 5. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat*
709 *Rev Microbiol.* 2020;18(6):344-59.
- 710 6. Bowers JR, Kitchel B, Driebe EM, MacCannell DR, Roe C, Lemmer D, et al. Genomic
711 Analysis of the Emergence and Rapid Global Dissemination of the Clonal Group 258 *Klebsiella*
712 *pneumoniae* Pandemic. *PLoS One.* 2015;10(7):e0133727.
- 713 7. Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, et al. Molecular
714 dissection of the evolution of carbapenem-resistant multilocus sequence type 258 *Klebsiella*
715 *pneumoniae*. *Proceedings of the National Academy of Sciences.* 2014;111(13):4988-93.
- 716 8. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, et al.
717 Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States:
718 clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother.*
719 2009;53(8):3365-70.
- 720 9. Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant
721 Enterobacteriaceae: The Impact and Evolution of a Global Menace. *J Infect Dis.*
722 2017;215(suppl_1):S28-S36.
- 723 10. Yang X, Dong N, Chan EW-C, Zhang R, Chen S. Carbapenem Resistance-Encoding and
724 Virulence-Encoding Conjugative Plasmids in *Klebsiella pneumoniae*. *Trends in Microbiology.*
725 2020.

- 726 11. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al.
727 Emergence and rapid global dissemination of CTX-M-15-associated *Klebsiella pneumoniae*
728 strain ST307. *J Antimicrob Chemother.* 2018;74(3):577-81.
- 729 12. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and
730 antimicrobial resistance of the KPC-producing *Klebsiella pneumoniae* ST307 clone. *Microb*
731 *Genom.* 2017;3(4):e000110.
- 732 13. Peirano G, Chen L, Kreiswirth BN, Pitout JDD. Emerging Antimicrobial Resistant High-
733 Risk clones among *Klebsiella pneumoniae*: ST307 and ST147. *Antimicrobial Agents and*
734 *Chemotherapy.* 2020;64(10).
- 735 14. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, et al. Distinct
736 evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of
737 *Klebsiella pneumoniae*. *PLoS Genet.* 2019;15(4):e1008114.
- 738 15. Long SW, Olsen, R. J., Eagar, T. N., Beres, S. B., Zhao, P., Davis, J. J., ... & Musser, J.
739 M. Population genomic analysis of 1,777 extended-spectrum beta-lactamase-producing
740 *Klebsiella pneumoniae* isolates, Houston, Texas: unexpected abundance of clonal group 307.
741 *MBio.* 2017;8(3):e00489-17.
- 742 16. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al. Genomic
743 analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella*
744 *pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci U S A.* 2015;112(27):E3574-
745 81.
- 746 17. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. Assembly of long, error-prone reads using
747 repeat graphs. *Nat Biotechnol.* 2019;37(5):540-6.
- 748 18. Vaser R, Sović, I., Nagarajan, N., & Šikić, M. Fast and accurate de novo genome
749 assembly from long uncorrected reads. *Genome research.* 2017;27(5):737-46.
- 750 19. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome
751 assemblies from short and long sequencing reads. *PLoS Comput Biol.* 2017;13(6):e1005595.
- 752 20. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al.
753 Integrative genomics viewer. *Nature biotechnology.* 2011;29(1):24-6.
- 754 21. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
755 arXiv preprint 2013:arXiv:1303.3997.
- 756 22. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics.*
757 2018;34(18):3094-100.
- 758 23. Seppey M, Manni M, Zdobnov EM. BUSCO: assessing genome assembly and annotation
759 completeness. *Methods in molecular biology (Clifton, NJ).* 2019;1962:227-45.
- 760 24. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the
761 quality of microbial genomes recovered from isolates, single cells, and metagenomes. *Genome*
762 *research.* 2015;25(7):1043-55.
- 763 25. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.*
764 2014;30(14):2068-9.
- 765 26. Wyres KL, Wick, R. R., Gorrie, C., Jenney, A., Follador, R., Thomson, N. R., & Holt, K.
766 E. . Identification of *Klebsiella* capsule synthesis loci from whole genome data. *Microbial*
767 *genomics.* 2016;2(12).
- 768 27. Wick RR, Heinz E, Holt KE, Wyres KL. Kaptive Web: User-Friendly Capsule and
769 Lipopolysaccharide Serotype Prediction for *Klebsiella* Genomes. *Journal of Clinical*
770 *Microbiology.* 2018;56(6):JCM.00197-18.

- 771 28. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, et al. Genetic
772 diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in
773 *Klebsiella pneumoniae* populations. *Microb Genom.* 2018.
- 774 29. Lam MMC, Wyres KL, Judd LM, Wick RR, Jenney A, Brisse S, et al. Tracking key
775 virulence loci encoding aerobactin and salmochelin siderophore synthesis in *Klebsiella*
776 *pneumoniae*. *Genome Medicine.* 2018;10(1):1-15.
- 777 30. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic
778 surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species
779 complex. *Nature Communications.* 2021;12(1).
- 780 31. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017:
781 expansion and model-centric curation of the comprehensive antibiotic resistance database.
782 *Nucleic Acids Res.* 2017;45(D1):D566-D73.
- 783 32. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, et al. In
784 silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence
785 typing. *Antimicrob Agents Chemother.* 2014;58(7):3895-903.
- 786 33. Tonkin-Hill G, Macalasdair N, Ruis C, Weimann A, Horesh G, Lees JA, et al. Producing
787 polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biology.* 2020;21(1).
- 788 34. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, Criscuolo A, Brisse S. Description
789 of *Klebsiella africanensis* sp. nov., *Klebsiella variicola* subsp. *tropicalensis* subsp. nov. and
790 *Klebsiella variicola* subsp. *variicola* subsp. nov. *Research in Microbiology.* 2019;170(3):165-70.
- 791 35. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:
792 improvements in performance and usability. *Mol Biol Evol.* 2013;30(4):772-80.
- 793 36. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
794 al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
795 Era. *Mol Biol Evol.* 2020;37(5):1530-4.
- 796 37. Kalyaanamoorthy S, Minh BQ, Wong TKF, Von Haeseler A, Jermin LS. ModelFinder:
797 fast model selection for accurate phylogenetic estimates. *Nature Methods.* 2017;14(6):587-9.
- 798 38. Lemoine F, Domelevo Entfellner JB, Wilkinson E, Correia D, Davila Felipe M, De
799 Oliveira T, et al. Renewing Felsenstein's phylogenetic bootstrap in the era of big data. *Nature.*
800 2018;556(7702):452-6.
- 801 39. Tonkin-Hill G, Lees JA, Bentley SD, Frost SDW, Corander J. RhierBAPS: An R
802 implementation of the population clustering algorithm hierBAPS. *Wellcome Open Res.*
803 2018;3:93.
- 804 40. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new
805 developments. *Nucleic Acids Res.* 2019;47(W1):W256-W9.
- 806 41. Drost H-G. Philentropy: Information Theory and Distance Quantification with R. *Journal*
807 *of Open Source Software.* 2018;3(26):765.
- 808 42. Martin Maechler PR, Anja Struyf, Mia Hubert, Kurt Hornik. cluster: Cluster Analysis
809 Basics and Extensions2021.
- 810 43. Abudahab K, Prada JM, Yang Z, Bentley SD, Croucher NJ, Corander J, et al. PANINI:
811 Pangenome Neighbour Identification for Bacterial Populations. *Microb Genom.* 2019;5(4).
- 812 44. Huerta-Cepas J, Forslund K, Coelho LP, Szklarczyk D, Jensen LJ, Von Mering C, et al.
813 Fast Genome-Wide Functional Annotation through Orthology Assignment by eggNOG-Mapper.
814 *Molecular Biology and Evolution.* 2017;34(8):2115-22.

- 815 45. Huerta-Cepas J, Szklarczyk D, Heller D, Hernández-Plaza A, Forslund SK, Cook H, et al.
816 eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource
817 based on 5090 organisms and 2502 viruses. *Nucleic Acids Research*. 2019;47(D1):D309-D14.
- 818 46. Grant JR, Arantes AS, Stothard P. Comparing thousands of circular genomes using the
819 CGView Comparison Tool. *BMC genomics*. 2012;13(1):202.
- 820 47. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. PHAST: A Fast Phage Search
821 Tool. *Nucleic Acids Research*. 2011;39(suppl):W347-W52.
- 822 48. Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, et al. PHASTER: a better, faster
823 version of the PHAST phage search tool. *Nucleic Acids Research*. 2016;44(W1):W16-W21.
- 824 49. Wickham H. *ggplot2: elegant graphics for data analysis* Springer-Verlag New York 2016.
- 825 50. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid
826 phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using
827 Gubbins. *Nucleic Acids Res*. 2015;43(3):e15.
- 828 51. Robertson J, Nash JHE. MOB-suite: software tools for clustering, reconstruction and
829 typing of plasmids from draft assemblies. *Microbial Genomics*. 2018;4(8).
- 830 52. Ondov BD, Treangen TJ, Melsted P, Mallonee AB, Bergman NH, Koren S, et al. Mash:
831 fast genome and metagenome distance estimation using MinHash. *Genome Biol*.
832 2016;17(1):132.
- 833 53. Hardiman CA, Weingarten RA, Conlan S, Khil P, Dekker JP, Mathers AJ, et al.
834 Horizontal Transfer of Carbapenemase-Encoding Plasmids and Comparison with Hospital
835 Epidemiology Data. 2016;60(8):4910-9.
- 836 54. Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer.
837 *Bioinformatics*. 2011;27(7):1009-10.
- 838 55. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, et al. Desirability
839 of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk
840 (RADAR). *Clin Infect Dis*. 2015;61(5):800-6.
- 841 56. Chen L, Mathema, B., Pitout, J. D., DeLeo, F. R., & Kreiswirth, B. N. Epidemic
842 *Klebsiella pneumoniae* ST258 is a hybrid strain. *mBio*. 2014;5(3):e01355-14.
- 843 57. Ocampo AM, Chen L, Cienfuegos AV, Roncancio G, Chavda KD, Kreiswirth BN, et al.
844 A Two-Year Surveillance in Five Colombian Tertiary Care Hospitals Reveals High Frequency of
845 Non-CG258 Clones of Carbapenem-Resistant *Klebsiella pneumoniae* with Distinct Clinical
846 Characteristics. *Antimicrob Agents Chemother*. 2016;60(1):332-42.
- 847 58. Bonura C, Giuffre M, Aleo A, Fasciana T, Di Bernardo F, Stampone T, et al. An Update
848 of the Evolving Epidemic of blaKPC Carrying *Klebsiella pneumoniae* in Sicily, Italy, 2014:
849 Emergence of Multiple Non-ST258 Clones. *PLoS One*. 2015;10(7):e0132936.
- 850 59. Geraci DM, Bonura C, Giuffre M, Saporito L, Graziano G, Aleo A, et al. Is the
851 monoclonal spread of the ST258, KPC-3-producing clone being replaced in southern Italy by the
852 dissemination of multiple clones of carbapenem-nonsusceptible, KPC-3-producing *Klebsiella*
853 *pneumoniae*? *Clin Microbiol Infect*. 2015;21(3):e15-7.
- 854 60. Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, et al. *Klebsiella*
855 *pneumoniae* ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid in a
856 resource-constrained healthcare setting. *Journal of Antimicrobial Chemotherapy*.
857 2020;75(4):896-902.
- 858 61. Lowe M, Kock MM, Coetzee J, Hoosien E, Peirano G, Strydom K-A, et al. *Klebsiella*
859 *pneumoniae* ST307 with blaOXA-181, South Africa, 2014–2016. *Emerging Infectious Diseases*.
860 2019;25(4):739-47.

- 861 62. Habib MA, Haque A, Nematzadeh S, Iversen A, Giske CG. High prevalence of 16S
862 rRNA methylase RmtB among CTX-M extended-spectrum β -lactamase-producing *Klebsiella*
863 pneumoniae from Islamabad, Pakistan. *International Journal of Antimicrobial Agents*.
864 2013;41(6):524-6.
- 865 63. Park DJ, Yu JK, Park KG, Park Y-J. Genotypes of ciprofloxacin-resistant *Klebsiella*
866 pneumoniae in Korea and their characteristics according to the genetic lineages. *Microbial Drug*
867 *Resistance*. 2015;21(6):622-30.
- 868 64. Castanheira M, Farrell SE, Wanger A, Rolston KV, Jones RN, Mendes RE. Rapid
869 expansion of KPC-2-producing *Klebsiella pneumoniae* isolates in two Texas hospitals due to
870 clonal spread of ST258 and ST307 lineages. *Microbial Drug Resistance*. 2013;19(4):295-7.
- 871 65. Black CA, So W, Dallas SS, Gawrys G, Benavides R, Aguilar S, et al. Predominance of
872 Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas.
873 *Frontiers in Microbiology*. 2021;11:3629.
- 874 66. Struve C, Bojer M, Krogfelt KA. Characterization of *Klebsiella pneumoniae* Type 1
875 Fimbriae by Detection of Phase Variation during Colonization and Infection and Impact on
876 Virulence. *Infection and Immunity*. 2008;76(9):4055-65.
- 877 67. Struve C, Bojer M, Krogfelt KA. Identification of a Conserved Chromosomal Region
878 Encoding *Klebsiella pneumoniae* Type 1 and Type 3 Fimbriae and Assessment of the Role of
879 Fimbriae in Pathogenicity. 2009;77(11):5016-24.
- 880 68. Khaertynov KS, Anokhin VA, Rizvanov AA, Davidiyuk YN, Semyenova DR, Lubin SA,
881 et al. Virulence Factors and Antibiotic Resistance of *Klebsiella pneumoniae* Strains Isolated
882 From Neonates With Sepsis. *Frontiers in Medicine*. 2018;5:225.
- 883 69. Clegg S, Murphy CN. Epidemiology and Virulence of *Klebsiella pneumoniae*.
884 *Microbiology Spectrum*. 2016;4(1).
- 885 70. Dolejska M, Villa L, Dobiasova H, Fortini D, Feudi C, Carattoli A. Plasmid content of a
886 clinically relevant *Klebsiella pneumoniae* clone from the Czech Republic producing CTX-M-15
887 and QnrB1. *Antimicrob Agents Chemother*. 2013;57(2):1073-6.
- 888 71. Heiden SE, Hübner N-O, Bohnert JA, Heidecke C-D, Kramer A, Balau V, et al. A
889 *Klebsiella pneumoniae* ST307 outbreak clone from Germany demonstrates features of extensive
890 drug resistance, hypermucoviscosity, and enhanced iron acquisition. *Genome Medicine*.
891 2020;12(1).

892 **Tables**

Table 1. Pangenomic Features of *K. pneumoniae*

Feature	CG258 (n = 37)	CG307 (n = 35)	Other CG (n = 23)	p-value^a
genome size (IQR)	5,695,223 (321,076)	5,551,257 (142,518)	5,666,705 (119,114)	0.0001
chromosome size (IQR)	5,322,183 (187,234)	5,357,994 (15,382)	5,302,444 (155,756)	0.3
GC content (IQR)	57.1 (0.2)	57.3 (0.1)	57.2 (0.2)	<0.0001
coding genes (IQR)	5,380 (269)	5,158 (139)	5,286 (120)	<0.0001
plasmids (IQR)	4 (2)	2 (1)	4 (3)	<0.0001
resistance genes (IQR)	5 (6)	7 (5)	9 (11)	0.3
resistance classes (IQR)	6 (3)	6 (1)	6 (7)	0.3
resistance score (SD)^b	2.1 (0.2)	1.9 (0.4)	1.6 (0.8)	0.01
virulence score (SD)^b	0.7 (1.0)	0 (0.0)	0.7 (1.4)	0.0006

CG – clonal group ; IQR – interquartile range; SD – standard deviation; median values are reported with IQR; means are reported with SD

^aKruskal-Wallis rank sum test p-value

^bComposite antimicrobial resistance and virulence scores based on scoring schema developed by Holt et al. Kleborate tool (<https://github.com/katholt/Kleborate>)

Table 2. Antimicrobial Resistance Features of 95 *K. pneumoniae* from Houston, TX

Feature	CG258 (n = 37) ^a	CG307 (n = 35) ^a	Other CG (n = 23) ^a	p-value ^b
Carbapenemases				<0.0001
<i>bla</i> _{KPC-2}	35 (94.6%)	31 (88.6%)	11 (47.8%)	
<i>bla</i> _{KPC-3}	2 (5.4%)	0 (0.0%)	2 (4.2%)	
<i>bla</i> _{NDM-1}	0 (0.0%)	0 (0.0%)	2 (4.2%)	
<i>bla</i> _{OXA-232}	0 (0.0%)	0 (0.0%)	1 (1.1%)	
ESBLs				<0.0001
<i>bla</i> _{CTX-M-15}	1 (2.7%)	35 (100%)	11 (47.8%)	
<i>bla</i> _{SHV-12}	30 (81.1%)	0 (0.0%)	0 (0.0%)	
<i>bla</i> _{SHV-27}	0 (0.0%)	0 (0.0%)	1 (4.3%)	
<i>bla</i> _{SHV-12} / <i>bla</i> _{CTX-M-15}	1 (2.7%)	0 (0.0%)	0 (0.0%)	
<i>ompK35/ompK36</i> changes ^c	37 (100%)	35 (100%)	5 (21.7%)	<0.0001
Aminoglycoside^d	36 (97.3%)	30 (85.7%)	15 (65.2%)	0.003
Tetracycline^d	2 (5.4%)	3 (8.6%)	9 (39.1%)	0.002
Sulfonamide^d	19 (51.4%)	16 (45.7%)	14 (60.9%)	0.5
Phenicol^d	14 (37.8%)	8 (22.9%)	9 (39.1%)	0.3
Fluoroquinolone^e	37 (100%)	35 (100%)	14 (60.9%)	<0.0001
Colistin^e	2 (5.4%)	3 (8.6%)	1 (4.3%)	0.9

^aCategorical responses include counts and percentages in parenthesis.

^bFisher's exact test p-value.

^cOuter membrane porin gene changes are counted if a truncation or nonsense mutation is detected in either the *ompK35* or *ompK36* gene.

^dAminoglycoside, tetracycline, sulfonamide, and phenicol predicted resistance based on presence of at least one gene that confers resistance to respective antibiotic class (e.g. *aac3-Ia* confers aminoglycoside resistance).

^eFluoroquinolone and colistin predicted resistance based on chromosomal mutations that confer resistance to each respective antibiotic class (e.g. truncations in *mgrB/pmrB* confer resistance to colistin). Small proportion of isolates (6/95; 6.3%) also carry quinolone resistance genes (i.e. *qnr* variants).

Table 3. Clinical Features and Outcomes of CG258 vs CG307 from Houston, TX

Feature	Sequence Type		p-value ^a
	ST258 (n=27)	ST307 (n=32)	
Age (SD)	60.7 (17.8)	63.4 (18.3)	0.72
Male (%)	14 (52)	11 (34)	0.20
Ethnicity			0.24
Hispanic or Latino	6 (22)	4 (13)	
Not Hispanic or Latino	18 (67)	27 (84)	
Unknown	2 (7)	0 (0)	
Not Reported	1 (4)	1 (3)	
Origin (%)			0.75
Home/Transfer outside US	20 (74)	24 (75)	
Long term acute care/ Hospital transfer	1 (4)	0 (0)	
Long term care Hospice	6 (22)	8 (25)	
Charlson score (SD)	2.6 (1.9)	3.6 (2.5)	0.13
Pitt score (SD)	2.6 (2.9)	1.7 (1.9)	0.30
Renal dysfunction (Yes) (%)	7 (26)	15 (47)	0.11
Culture source			0.068
Blood	4 (15)	0 (0)	
Respiratory	7 (26)	4 (13)	
Urine	10 (37)	21 (66)	
Wound	3 (11)	4 (13)	
Other	3 (11)	3 (9)	
Infection (Yes) (%)	6 (22)	9 (28)	0.77
Hospital Duration (Days) (SD)	13.9 (14.8)	10.8 (7.9)	0.96
30-day Mortality (%)	8 (30)	1 (3)	0.008

SD – standard deviation; LTAC – Long-term acute care


^aContinuous outcomes tested with Wilcoxon rank sum test; Categorical outcomes tested with Fisher’s exact test

Table 4. IPW-adjusted DOOR categories for Houston, TX

	ST258	ST307	Cumulative Difference (ST307 – ST258)
Alive without events (%)	15 (54)	24 (74)	20 (3, 37)
Alive with 1 event (%)	3 (12)	6 (20)	29 (15, 42)
Alive with 2 or 3 events (%)	1 (3)	1 (3)	29 (17, 42)
Dead (%)	8 (32)	1 (3)	
	IPW-adjusted DOOR probability estimate (95% bootstrap CI)		
ST307 vs. ST258 (%)	64 (48, 79)		


IPW – inverse-probability weighted; DOOR – Desirability of Ordinal Outcome Ranking; CI – Confidence Interval

893 **Figures**




894

895 **Fig. 1** Core Gene Pangenomic Population Structure of 94 CRKP isolates in the Houston, TX
 896 cohort. Maximum likelihood phylogenetic tree demonstrating the two predominant co-circulating
 897 clades, CG258 (blue clade) and CG307 (red clade). Internal node bootstrap values of $\geq 95\%$ are
 898 denoted as black circles. Label backgrounds indicate the 6 hierarchical clustering groups
 899 identified using Bayesian analysis of population structure. Clonal groups associated with each
 900 hierarchical group are as follows: CG258 (blue); CG307 (red); CG147 (green); CG15 (pink);
 901 CG20 (purple); other CGs (yellow). First column indicates each of the ten hospital sites in
 902 Houston, TX. Second column indicates carbapenemase carriage. The third column indicates if
 903 carbapenemase carriage was chromosomal. The final 13 columns indicate the plasmid vectors
 904 that were identified to have at least one sample with carbapenemase carriage. Carbapenemase
 905 carriage of each plasmid vector is distinguished by carbapenemase positive (filled shape) and
 906 carbapenemase negative (empty shape).



907


908 **Fig. 2** Core SNP inferred ML phylogenies of CG258 and CG307 isolates. Internal node bootstrap values of $\geq 95\%$ are denoted as
 909 black circles. Isolate label backgrounds indicate hierarchical clustering groups identified using Bayesian analysis of population
 910 structure for each respective sub-lineage. Legend designations are as follows: (1) region from which isolate was collected, (2) capsular
 911 synthesis/LPS allele type, (3) ICEKp variant with yersiniabactin and colibactin gene cluster lineages listed respectively, (4)
 912 carbapenemase carriage status, (5) ESBL carriage (CG258)/*bla*_{CTX-M-15} copy number (CG307). **(A)** CG258 core SNP phylogeny using
 913 a reference-based alignment with C268 isolate. **(B)** CG307 core SNP phylogeny using reference-based alignment with C246 isolate.
 914 Stars within *bla*_{CTX-M-15} copy number column (*i.e.* column 5) indicate isolate with one truncated *bla*_{CTX-M-15} copy.



915


916 **Fig. 3** Population structure of previously characterized CG307 isolates with the CG307 Houston
917 CRACKLE II isolates. Maximum likelihood inferred phylogeny of CG307 isolates (n=798)
918 using C234 as a reference for core gene alignment. Branch label background corresponds to
919 hierBAPS predicted clade. Outer ring indicates region where isolate was collected. Clades I, III,
920 and IV are predominantly made up of Houston isolates. Clade II is disseminated worldwide and
921 shares a paraphyletic relationship with Clade I.

922
923



924

925 **Fig. 4** Clustering of CRKP isolates with predicted protein functional characterization of the accessory genome. (A – B) t-distributed
 926 Stochastic Neighbor Embedding (t-SNE) 2-D plot of accessory genome clustering of CRKP isolates. Clonal group is indicated by shape. ‘+’
 927 Georgia isolate (C682) that clusters with Houston CG307 isolates. (A) geographical region stratification of isolates. (B) Cluster group
 928 prediction (k=4) using a PAM algorithm to determine cluster assignment. ‘*’ Exceptions to CG258 cluster-to-clade correlation. (C) Stacked
 929 bar-chart of Cluster of Orthologous Genes (COGs) functional category proportions based on annotated genes found in the accessory
 930 genome. ‘n’ above each group indicates number of genes identified in each respective clonal group. Proportion of functionally annotated
 931 accessory genes differ significantly across pairwise comparisons of clonal groups as demonstrated in scatter plot (D) which plots CG258 vs
 932 CG307 relative frequency proportions of COG functional groups denoted by the COG group letter (defined in C) with significant adjusted
 933 p-values indicated for greater proportion of CG258 (blue) or CG307 (red) for each respective group labelled accordingly. These COG
 934 function group proportions exclude ‘S – unknown function’ and ‘undefined homologs’. Non-significant COG functional group differences
 935 are labelled in grey.



936
 937 **Fig. 5** Dendrogram and Heatmap of Plasmidome Mash distances. Legend for row and column labels listed to the left of each
 938 respective graph. Each dendrogram is constructed through agglomerative hierarchical clustering using an ‘average’ linkage. **(A)**
 939 Plasmidome mash distance matrix by isolate (n = 119). Legend is labeled as follows: (1) Region; (2) Clonal Group; (3)
 940 Carbapenemase. There is a noted primary clustering group of CG258 isolates (blue labeled clade) whereas there are two Houston-
 941 based CG307 clustering groups (red labeled clades) with diffuse clustering occurring with other CGs. **(B)** Plasmidome mash distance
 942 matrix by plasmid type (n = 295) with small, primarily ColE1-like plasmids excluded from analysis. Legend is labeled as follows: (1)
 943 Region; (2) Clonal Group; (3) Plasmid Type; (4) Carbapenemase. This analysis shows clustering of primarily CG258 X2 type
 944 plasmids, multi-replicon FIIK type plasmids, and pKpQIL plasmids indicated with blue labelled cluster groups. This is contrast to one
 945 primary CG307 plasmid cluster group which includes R type plasmids as well the novel pCG307_HTX plasmid associated with the
 946 Houston group.